Using a novel Enpp1 inhibitor that can be delivered orally and results in on-target inhibition of Enpp1 activity in mice, we demonstrate that Enpp1-targeted therapy improves tumor control by radiation therapy in these cancers. This evidence concerns the gene ENPP1 and cancer.